(Reuters) – The U.S. Food and Drug Administration (FDA) asked Dutch medical equipment maker Philips Respironics on Thursday to notify patients about the company’s recall of certain ventilators ...

Despite a €982 million settlement provision for Respironics, adjusted operating income showed improvement in Q1 2024. Philips aims for 3-5% sales growth and 11-11.5% EBITDA margin in 2024, with ...

FDA warns of potential risks to patients as thousands of Philips Respironics' ventilators face issues with inoperative alarms. 65 deaths have been reported.

Philips Respironics to lay off and relocate hundreds of Pittsburgh-area employees 02:14. PITTSBURGH (KDKA) -- Workers at Phillips Respironics, which has employees at multiple locations all ...

Philips Respironics is in the process of closing some facilities in western Pennsylvania.Related video above: The fight to replace recalled Philips CPAP machine A spokesperson confirmed to ...

Philips Respironics agreed to pay $1.1 billion to address claims filed in US courts and potential claims submitted through the census registry; the company has not admitted any fault or liability ...

Philips Respironics announced that it agreed to pay over a billion dollars to settle claims stemming from the 2021 U.S. recall of its sleep therapy devices.

Philips and Philips Respironics will pay $1.1 billion to settle personal injury litigation in the United States in connection to the issues over its sleep therapy devices.

Philips settles $1.1 billion in Respironics ventilator recall lawsuit. Updates on Philips' Q1 performance and 2024 guidance. PHG shares surge 36.9% in premarket trading.

Philips has reached a $1 billion settlement in the U.S. related its Respironics ventilators, and backed its full-year guidance. The company made the disclosure as it reported a net loss for the ...

Philips Respironics and Philips Holding USA agreed to the FDA’s finalized consent decree against the company, according to a company press release.This announcement comes a few months after ...

Philips Respironics will continue to prioritize completing the remediation of the sleep and respiratory care devices under Respironics’ voluntary June 2021 recall. More than 99% of the actionable ...